Sotrovimab News and Research

RSS

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

Researchers developed a novel, rapid and accurate qRT-PCR-based method to detect Omicron sublineages BA.1/BA.1.1 and BA.2 in patient samples.

18 Jul 2022

SARS-CoV-2 Omicron BA.5 tropism shifting back to ancestral strains

In a recent study posted to the medRxiv* pre-print server, researchers from Australia and Switzerland gathered data to help track and manage ongoing and future infection waves by new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron globally.

12 Jul 2022

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

A new study successfully identified a potent neutralization epitope in SARS-related coronaviruses.

6 Jul 2022

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

A recent study posted to the bioRxiv* preprint server supports using mosaic sarbecovirus receptor-binding domain (RBD)-nanoparticles to discover therapeutic pan-variant and pan-sarbecovirus monoclonal antibodies (mAbs) and to induce mAbs by vaccination.

30 Jun 2022

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

In a recent study published in The Lancet Infectious Diseases, researchers investigated the neutralization sensitivity of the emerging Omicron sub-variants, BA.2.12.1, BA.4, and BA.5.

30 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

Scientists analyzed the antigenic characteristics of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 and BA.4 sublineages.

27 May 2022

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Researchers compared the efficacy of sotrovimab and molnupiravir in preventing severe COVID-19 outcomes among non-hospitalized and high-risk COVID-19 patients across England.

25 May 2022

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

A recent article posted to the bioRxiv* preprint server demonstrated structural underpinnings of the neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants by 002-S21F2, an extensive SARS-CoV-2 neutralizing antibody.

18 May 2022

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

15 May 2022

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

A new study analyzed the imprinted antibody responses towards the SARS-CoV-2 Omicron subvariants.

12 May 2022

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Researchers depicted the efficacy of the SARS-CoV-2 monoclonal antibodies (mAbs) against the SARS-CoV-2 Omicron variant.

11 May 2022

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination

10 May 2022

Sotrovimab News and Research

Researchers develop a rapid, specific, and accurate RT-qPCR-based method to detect and distinguish between Omicron sublineages

SARS-CoV-2 Omicron BA.5 tropism shifting back to ancestral strains

SARS-CoV-2 RBD vulnerability discovered - target for antibodies against variants

Mosaic-8 RBD-nanoparticles show promise against current and future SARS-CoV-2 variants

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Exploring antigenic traits of SARS-CoV-2 Omicron BA.5 and BA.4 subvariants

The effectiveness of sotrovimab vs. molnupiravir in preventing severe COVID-19 outcomes in non-hospitalized high-risk COVID-19 adult patients

Discovery of a potent SARS-CoV-2 RBD specific human monoclonal antibody

Super-antibody UT28K shows broad-spectrum activity against SARS-CoV-2 variants

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

mRNA boosters enhance neutralization of SARS-CoV-2 BA.1, BA.2 and BA.3

The war against COVID-19: reinfection, vaccines, and herd immunity

The sensitivity of Omicron subvariants to therapeutic monoclonal antibodies

SARS-CoV-2 BA.2 poses greater risk to global health than BA.1

Clinical characteristics of immunocompromised patients infected with the SARS-CoV-2 Omicron variant

Bebtelovimab potently neutralizes all SARS-CoV-2 variants of concern

Treating COVID-19 using monoclonal antibodies during pregnancy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News